Michele Senni

2 months ago | onlinelibrary.wiley.com | Michele Senni |Victor Shi |Michael Bohm |Pratap Paruchuru

Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), is recommended by the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America guideline for heart failure (HF) in patients with HF with reduced ejection faction, New York Heart Association class II−III, and by the 2021 European Society of Cardiology (ESC) guidelines to replace angiotensin-converting enzyme inhibitors (ACEIs) for reducing HF hospitalizations and death risk.1, 2...

Nov 17, 2024 | jamanetwork.com | Orly Vardeny |Outcomes Research |Brian Claggett |Michele Senni

Key PointsQuestion  What is the treatment effect of finerenone, relative to placebo, in patients with heart failure with mildly reduced or preserved ejection fraction based on postrandomization potassium levels? Findings  Among 6001 patients in a clinical trial, finerenone increased potassium levels greater than 5.5 mmol/L and decreased potassium levels less than 3.5 mmol/L.

Oct 28, 2024 | nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03264-4, published online 1 September 2024. In the version of the article initially published, the first three columns of the “New-onset atrial fibrillation” row of Fig. 1 originally read “286 (3.0)”, “1.3”, “345 (3.6)” and have now been amended to “286 (3.9)”, “1.4”, “345 (4.7)” in the HTML and PDF versions of the article.

Sep 27, 2024 | jamanetwork.com | Muthiah Vaduganathan |Brian Claggett |Michele Senni

Key PointsQuestion  What are the long-term expected effects of treatment with the nonsteroidal mineralocorticoid receptor antagonist, finerenone, in patients with heart failure with mildly reduced or preserved ejection fraction?

Sep 1, 2024 | nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more

AbstractCardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease, and diabetes. The non-steroidal mineralocorticoid receptor antagonist, finerenone, has been studied in three prospective randomized clinical trials of patients with cardio-kidney-metabolic syndrome: FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF.